Case Report
Abiraterone-Induced Rhabdomyolysis in Prostate Cancer: A Report of Two Cases and Review of the Lierature
Sanaz Ghafouri* and Alexandra Drakaki
Department of Internal Medicine, University of California, USA
*Corresponding author: Sanaz Ghafouri, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, 90095, CA, USA
Published: 05 Jul, 2018
Cite this article as: Ghafouri S, Drakaki A. Abiraterone-
Induced Rhabdomyolysis in Prostate
Cancer: A Report of Two Cases and
Review of the Literature. Ann Clin Case
Rep. 2018; 3: 1533.
Abstract
Background: Abiraterone is a hormone targeted treatment that is used along with the standard
androgen deprivation therapy for castration-resistant prostate cancers and has recently been proven
to improve survival outcomes when used for castration-sensitive prostate cancers as well. However,
to date, there is little literature on a fatal complication of this medication, which is rhabdomyolysis.
Patient Description: We report a case series of two patients, a 72-year-old and an 80-year-old male,
both with metastatic castration-resistant prostate cancers who developed rhabdomyolysis within
a few weeks of starting Abiraterone. Both individuals showed significant recovery shortly after
discontinuation of Abiraterone.
Conclusion: This case highlights the importance of recognizing rhabdomyolysis early in patients
started on Abiraterone, as this serious complication may be more common than previously
suspected. This association becomes particularly important clinically now that there will be an
increased frequency in the use of Abiraterone given recent studies showing its benefits when started
early for patients with castration-sensitive prostate cancers as well.
Introduction
Castration Resistant Prostate Cancer (CRPC), defined as disease progression while on Androgen
Deprivation Therapy (ADT), as evidenced by increasing PSA, new metastasis or progression of
existing metastasis, is commonly treated with novel hormone targeting agents, such as Abiraterone
and Enzalutamide, in addition to continuation of ADT. Recently, the LATITUDE trial supports
the addition of Abiraterone to ADT for castration-sensitive prostate cancer (CSPC) as well, which
could mean that Abiraterone will be used more frequently in early prostate cancers [1]. Since the
CYP17A1 inhibitor Abiraterone became FDA approved in 2011 for the treatment of CRPC, there
has been few case reports in the literature of an association between the drug and rhabdomyolysis.
Considering that the mortality rate of rhabdomyolysis can be as high as 30%, it is important to bring
awareness of this association as early recognition and discontinuation of this agent could prevent
long term complications [2].
We present two cases of patients with CRPC started on Abiraterone who developed
rhabdomyolysis within the first few weeks of treatment initiation. Fortunately, the association with
Abiraterone was recognized immediately, and the medication was discontinued, leading to resolution
of rhabdomyolysis without further complications for these individuals. This report serves to identify
patients who are most at risk for the development of Abiraterone-induced rhabdomyolysis, and to
recognize that perhaps this complication is more common than previously suspected.
Case Presentation 1
A 72-year-old Caucasian male with a history of essential hypertension, type II diabetes, prior
strokes with residual neurologic deficits, recently diagnosed and treated for non-muscle invasive
bladder cancer and prostate cancer (Gleason 8) with widespread metastasis to the bone presented
to an outside hospital with generalized weakness after a couple of weeks of starting standard dose
Abiraterone with prednisone.
The patient underwent radical prostatectomy at the time of diagnosis 12 years ago, with salvage
radiation therapy for a biochemical relapse 2 years later. He developed metastatic disease to the bone
and retroperitoneal lymph nodes 3 years ago, for which he was treated initially with a combination
of Androgen Deprivation Therapy (ADT) with leuprolide acetate and bicalutamide, followed by
discontinuation of bicalutamide and short-term benefit due to withdrawal effect. Due to rising PSA and poor performance status, he was started on Abiraterone
with prednisone. However, within the first few weeks of being on
treatment, his performance status declined further and presented to
an outside hospital for evaluation.
On admission to the hospital, he was found to have progressively
worsening weakness, rigidity and muscle pain. He had an EMG
study showing myopathy with membrane instability, Creatinine
Kinase (CK) elevated to 24,918, transaminitis with AST being 550
and ALT being 331, acute renal insufficiency with Creatinine of 3.0
from baseline Creatinine of 1.2, and urinalysis showing a significant
amount of blood without RBCs. All these findings were concerning
for rhabdomyolysis, with the most likely etiology attributed to
Abiraterone as he has not started on any other medication or has
not had any strenuous activity. Abiraterone was discontinued and
patient started on high dose steroids, aggressive hydration with
marked improvement in his rigidity and strength. After hospital
discharge, his aforementioned lab abnormalities resolved, and his
strength continued to improve with physical therapy. He has initiated
treatment with the androgen-receptor antagonist Enzalutamide, and
has been tolerating it well thus far, without recurrent episodes of the
rhabdomyolysis.
Case Presentation 2
An 80-year-old Caucasian male with stage 3 chronic kidney
disease and metastatic prostate cancer presented the hospital with
abdominal pain, discovered to have pyelonephritis and a mild case of
rhabdomyolysis in the setting of being for two months on Abiraterone
and prednisone for castrate resistant prostate cancer.
The patient underwent in an outside facility neoadjuvant
chemotherapy and ADT, followed by radical prostatectomy and lymph
node dissection for high risk prostate cancer (Gleason 9) fifteen years
prior to this presentation. He remained on Leuprolide intermittently
for persistently elevated PSA levels and upon seeking second opinion;
he underwent staging evaluation that revealed metastatic disease to
the bones, as well as pelvic and retroperitoneal lymphadenopathy. At
this time, Abiraterone and prednisone were added to the Leuprolide,
and had been tolerating that regimen well for several weeks up until
he developed weakness along with abdominal pain and nausea that
lead him to present to the ED.
On admission to the hospital, he had a CT of the abdomen and
pelvis for work up of his abdominal pain that showed perinephric
stranding, as well as urinalysis concerning for pyelonephritis.
He developed hematuria but given the concomitant generalized
weakness, he had a gradually up-trending CK and Creatinine,
concerning for new onset rhabdomyolysis. He was empirically
treated with Vancomycin and Zosyn and narrowed to Ciprofloxacin
when his urine culture sensitivities resulted. He was on Crestor prior
to admission for hyperlipidemia, which was discontinued, and he was
given IV fluids. Initially, the Abiraterone was continued as it was felt
that the antibiotics were the possible cause of his rhabdomyolysis;
however, despite the previously mentioned interventions, his CK uptrended
to 4,219 and his Creatinine increased to 3.4, from a baseline
of 1.2. At this time, the Abiraterone was discontinued. On discharge,
the CK and Creatinine had normalized, and he never had recurrence
of any of those symptoms.
One month later, he was restarted on the Abiraterone given that
the lab abnormalities had resolved, however, this was discontinued
shortly after as he started developing abdominal pain concerning
that he will have recurrent event. Patient enrolled on an institutional
radiation oncology protocol for treatment of oligometastatic disease
and in conjunction with single agent Leuprolide is maintaining an
almost undetectable PSA level.
Discussion
According to the American Society of Clinical Oncology,
recommended treatment for CRPC includes continuing androgen
deprivation therapy indefinitely, along with targeted therapies, such as
Abiraterone/Prednisone or Enzalutamide, or bone-targeted therapies
with radium-223, which have all shown to improve overall survival,
quality of life, with the reported toxicity. Systemic chemotherapy with
a docetaxel-based regimen could also be offered in the right patient
population butis associated with increased toxicities [3]. Furthermore,
Taylor et al. performed a retrospective multivariate analysis of 341
patients from four clinical trials of secondary therapy for CRPC and
found that when Abiraterone or Enzalutamide was combined with
continued ADT, patients had a median survival benefit of 2-6 months
compared to those without ADT, supporting the recommendation to
continue ADT [4].
In addition to the survival benefits of Abiraterone for CRPC,
the 2017 phase III LATITUDE trial recently supports its use for
castration-sensitive prostate cancers. When comparing ADT,
Abiraterone and prednisone to the standard ADT for men with newly
diagnosed metastatic prostate cancer, Fizazi et al. [1] reported a 38%
lower chance of death in the Abiraterone group. Abiraterone also
more than doubled the median time of when the cancer progressed,
from 14.8 months to 33 months. These findings could support more
frequent use of Abiraterone for early metastatic prostate cancers.
Moreover, a systematic review and meta-analysis on 2,283
patients with CRPC from 10 trials showed that Abiraterone
significantly prolonged overall survival, radiographic progression
free survival, and time to progression without any unexpected
toxicities [5]. Furthermore, the STAMPEDE trial found that men
with locally advanced or metastatic prostate cancer who were treated
with ADT and Abiraterone/Prednisone compared to ADT alone had
71% improvement in the time to treatment failure, correlating to 37%
improvement in overall survival [6].
Despite its effectiveness in treating CRPC, Abiraterone’s
mechanism of action can largely contribute to the risk for
rhabdomyolysis that has been underreported. Abiraterone is a
CYP17A1 inhibitor that functions by blocking production of
androgens in the prostate, testicles and adrenal glands. It works by
inhibiting cytochrome P450 17 alpha-hydroxylase (CYP17), which in
turn decreases cortisol production, as well as the intended effect of
decreasing androgen production. This decrease in cortisol leads to an
increased production of ACTH and mineralocorticoids by removing
the negative feedback effect from the cortisol, which in turn can lead
to hypokalemia. Hypokalemia is a known major adverse effect of
abiraterone but is also a major risk factor for rhabdomyolysis [7-8].
Rhabdomyolysis is caused by muscle breakdown, which leads to
leakage of proteins, electrolytes and myoglobin into the bloodstream,
leading to complications such as acute kidney injury. Risk factors
include advanced age, chronic kidney disease, diabetes, hypokalemia,
dehydration, recreational drugs, severe exertion, trauma or crush
injuries, certain viral infections, and prescription drugs like statins
and antipsychotics [9]. It is critically important for internists and
oncologist prescribing all the aforementioned medications to be aware of the precipitating and pre-existing factors that are fairly
common in this patient population. The aim of this case reports is
to enrich the literature given that there is lack of reporting of this
potentially life-threatening condition that is reversible with early
recognition and treatment.
Acknowledgments
We would like to thank the subjects in the case series who fortunately recovered from the complication of Abiraterone but were able to shed light on a significant adverse effect to be made aware of for prospective patients.
References
- Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, Boris Y Alekseev, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017; 377: 352-360.
- Melli G, Chaudhry V, Cornblath. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005; 84: 377-385.
- Ethan Basch, D Andrew Loblaw, Thomas K Oliver, Michael Carducci, Ronald C Chen, James N Frame, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer : American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol. 2014; 32: 3436-3448.
- Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993; 11: 2167-2172.
- Zhou Z, Liu SX, Zhang TS, Xia J, Li B. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014; 15: 1313-1320.
- Nicholas D James, Johann S de Bono, Melissa R Spears, Noel W Clarke, Malcolm D Mason, David P Dearnaley, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017; 377: 338-351.
- Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther. 2012; 6: 13-18.
- Hoy SM. Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer. Drugs. 2013; 73: 2077-2091.
- Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve. 2002; 25: 332-347.